News | October 03, 2011

JenaValve First to Receive CE Mark for Second-Generation Transapical TAVI System

October 3, 2011 — JenaValve Technology GmbH, a German company specializing in the development of transcatheter heart valve implantation (TAVI) systems, received CE mark approval for its second-generation transapical TAVI. This system is used to treat severe aortic valve stenosis in elderly high-risk patients, especially in patients for whom conventional open-heart surgery is not an option.

The pivotal CE-marking study is a prospective, multicenter, uncontrolled clinical trial comprising 73 patients with severe symptomatic aortic valve stenosis, which was held at seven German study sites between October 2010 and July 2011. The primary endpoint of the trial was the 30-day mortality rate. The secondary endpoints were the rate of successful implantation, as well as further parameters for performance and safety of the prosthetic heart valve. The first results of the study's primary endpoint are being presented at the pre-eminent EACTS scientific meeting on Oct. 3, 2011, in Lisbon.

In his podium presentation, cardiac surgeon Hendrik Treede, M.D., from the University Heart Center in Hamburg will present the study data ("Safety and efficacy outcomes from the multicenter CE-mark study using the JenaValve second-generation transcatheter aortic valve implantation (TAVI) system"). The presentation will take place at 11:45 in Auditorium 1 at the Lisbon Congress Center.

Prof. Friedrich-Wilhelm Mohr, M.D., medical director of the department of cardiac surgery at the University of Leipzig Heart Center, is the principal investigator of the multicenter study. "The study appears to be progressing very promisingly, and the 30-day trial data support the safety and efficacy of the JenaValve system. Now patients have access to a new generation system for transapical TAVI treatment. The JenaValve design allows the cardiac surgeon and cardiologist to achieve precise positioning and allows repositioning of the heart valve prosthesis with its unique, patented positioning feelers. It is with these key features that the system distinguishes itself from its competitors,” said Mohr.

The transapical TAVI system consists of both the Cathlete delivery system and The JenaValve heart valve prosthesis. The product is available in three sizes and covers aortic annulus diameters from 21 to 27 mm.

For more information: www.jenavalve.de

 

Related Content

The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventi
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt.
SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company of India focused on cardiology, announced it Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. #SMT #HYDRA #TAVR

The self-expanding SMT Hydra transcatheter aortic valve replacement (TAVR) device.

Feature | Heart Valve Technology | June 09, 2020
June 9, 2020 — SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company in India focused on
News | Heart Valve Technology | June 08, 2020
June 8, 2020 — Edwards Lifesciences Corp.
Edwards Lifesciences Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe
News | Heart Valve Technology | May 18, 2020
May 18, 2020 — The Edwards Lifesciences Corp.
Key TAVR Takeaways From ACC 2020
Feature | Heart Valve Technology | April 20, 2020 | Dave Fornell, Editor
Some U.S.
Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 
Feature | Heart Valve Technology | April 09, 2020
April 9, 2020 — Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European
The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Edwards Lifesciences Corp.
Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR

Conclusions from the real world TAVR vs. surgery trial for aortic valve replacement outcomes in the U.K., presented by William D. Toff, M.D. at ACC 20. 

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) di